

# Training Exercise: Post-GWAS Analysis    KidneyGenAfrica Training Programme

Jean-Tristan Brandenburg

January 2026

## Contents

<b>1</b>	<b>Post-GWAS Analysis – Context</b>	<b>2</b>
<b>2</b>	<b>Examples of Post-GWAS Analyses</b>	<b>2</b>
<b>3</b>	<b>Software, Platforms, and Technical Approaches</b>	<b>2</b>
3.1	Manual Analysis . . . . .	2
3.2	Pipelines and Workflows . . . . .	3
3.3	Web-Based Platforms . . . . .	3
<b>4</b>	<b>Annotation and Post-GWAS Interpretation Using FUMA</b>	<b>3</b>
4.1	General Description . . . . .	3
4.2	FUMA Modules . . . . .	4
4.3	SNP2GENE: Definition of SNPs and Loci . . . . .	4
4.3.1	Independent Significant SNPs . . . . .	4
4.3.2	Lead SNPs . . . . .	4
4.3.3	Genomic Risk Loci . . . . .	4
4.3.4	Candidate SNPs . . . . .	4
4.4	Functional Annotation Tables . . . . .	5
4.5	Gene-Based Analysis Using MAGMA . . . . .	5
4.6	Visualization . . . . .	5
4.6.1	Genome-Wide Plots . . . . .	5
4.6.2	Gene-Based Plots . . . . .	5
4.6.3	Regional Association Plots . . . . .	5
4.7	Interpretation and Limitations . . . . .	5
<b>5</b>	<b>Exercise</b>	<b>6</b>
5.1	Dataset Description . . . . .	6
5.2	FUMA Parameters . . . . .	6
5.3	Questions . . . . .	6

# 1 Post-GWAS Analysis – Context

Post-GWAS analysis refers to the set of analyses performed **after a genome-wide association study (GWAS)** to interpret and translate GWAS signals into biological insights.

Post-GWAS analyses aim to **extract, understand, and interpret association results at multiple levels**, including significant genomic regions, variants, and genes. These analyses typically rely on **GWAS summary statistics, linkage disequilibrium (LD) information**, and/or **genotype data**, combined with external biological databases and specialized software.

## 2 Examples of Post-GWAS Analyses

*(non-exhaustive list)*

- Assessment of association quality and bias using genomic inflation factors ( $\lambda$ ), QQ plots, and Manhattan plots
- Extraction of significant SNPs and fine-mapping to identify putative causal variants
- Functional annotation and visualization of variants
- Replication of known associations and validation of novel signals
- Gene-based and gene-set association analyses
- Variant-to-gene mapping using eQTLs and chromatin interaction data
- Pathway and tissue-specific enrichment analyses

### More advanced analyses

- Polygenic risk score (PRS) construction and validation
- Mendelian randomization
- Multi-omics integration (transcriptomics, epigenomics, proteomics)

## 3 Software, Platforms, and Technical Approaches

Post-GWAS analyses rely on a wide range of tools and strategies. The choice depends on the research question, available data, and computational resources.

### 3.1 Manual Analysis

Manual analysis involves running each step independently. This approach is **flexible and transparent** but **time-consuming** and prone to human error.

## Common tools

- **PLINK** – SNP filtering, clumping
- **GCTA** – conditional analysis, heritability
- **LocusZoom** – regional association plots
- **FINEMAP**, **SuSiE**, **CAVIAR** – fine-mapping
- **ANNOVAR**, **VEP** – variant annotation
- **MAGMA** – gene and gene-set analysis
- **R / Python** – custom analyses

## 3.2 Pipelines and Workflows

Automated workflows deployed on local machines, HPC clusters, or cloud infrastructure. These are **reproducible and scalable** but require maintenance.

### Example

- **H3AGWAS pipeline** – GWAS and post-GWAS workflows for African genomics

## 3.3 Web-Based Platforms

Web platforms provide predefined pipelines with minimal computational burden but reduced flexibility.

### Example

- **FUMA** – functional mapping, annotation, and gene prioritization

# 4 Annotation and Post-GWAS Interpretation Using FUMA

## 4.1 General Description

Functional Mapping and Annotation of Genome-Wide Association Studies (FUMA) is a web-based platform for annotating, prioritizing, visualizing, and interpreting GWAS results using summary statistics.

FUMA integrates LD information, functional annotations, eQTLs, chromatin interactions, and gene-based association analyses. User registration is required to upload private datasets, while public results can be explored freely.

Tutorial: <https://fuma.ctglab.nl/tutorial>

## 4.2 FUMA Modules

- **SNP2GENE**: identification of significant SNPs, locus definition, functional annotation, and MAGMA analyses
- **GENE2FUNC**: biological interpretation of gene lists (expression and pathways)
- **Cell Type**: identification of relevant cell types using MAGMA results

## 4.3 SNP2GENE: Definition of SNPs and Loci

### 4.3.1 Independent Significant SNPs

Independent significant SNPs:

- Have  $P \leq 5 \times 10^{-8}$  (default)
- Are independent at  $r^2 \leq 0.6$

These SNPs correspond to PLINK-clumped SNPs and serve as anchors for downstream analyses.

### 4.3.2 Lead SNPs

Lead SNPs are independent significant SNPs that are independent at a stricter threshold ( $r^2 < 0.1$ ). They represent the most independent association signals.

### 4.3.3 Genomic Risk Loci

Lead SNPs are grouped into genomic risk loci:

1. SNPs in LD ( $r^2 \geq 0.1$ ) are grouped
2. Nearby loci (default: 250 kb) are merged
3. The SNP with the smallest P-value represents the locus

### 4.3.4 Candidate SNPs

Candidate SNPs:

- Are in LD with independent significant SNPs
- Pass an optional GWAS threshold (default  $P \leq 0.05$ )

They are fully annotated and used for gene mapping.

## 4.4 Functional Annotation Tables

- **SNPs annotation:** all candidate SNPs with functional information
- **ANNOVAR:** predicted functional consequences
- **Mapped genes:** genes mapped by positional, eQTL, or chromatin interaction mapping
- **eQTL mapping:** SNP–gene–tissue combinations
- **GWAS Catalog:** overlap with published GWAS associations

## 4.5 Gene-Based Analysis Using MAGMA

FUMA performs MAGMA gene-based, gene-set, and gene-property analyses using default parameters (SNP-wise mean model).

SNPs are assigned to genes based on physical position, and gene-level association statistics are computed using the selected reference panel.

## 4.6 Visualization

### 4.6.1 Genome-Wide Plots

Manhattan plots are generated from GWAS summary statistics. SNPs with  $P \geq 1 \times 10^{-5}$  are excluded, and overlapping points are filtered for clarity.

### 4.6.2 Gene-Based Plots

Gene-level Manhattan plots are generated using MAGMA (v1.10) considering protein-coding genes from Ensembl build 85.

### 4.6.3 Regional Association Plots

Regional plots can be generated for independent significant SNPs, lead SNPs, or genomic risk loci.

Alternative tools:

- LocusZoom v2: <http://locuszoom.org/>

## 4.7 Interpretation and Limitations

LD-based definitions provide approximations of association signals. Lead SNPs are not necessarily causal, and multiple biological signals may be merged into a single locus.

Bayesian fine-mapping approaches offer a more precise framework to identify causal variants and define credible sets.

## 5 Exercise

### 5.1 Dataset Description

The dataset includes approximately **67,000 African American individuals** from a meta-analysis of eight cohorts generated using METAL.

Data access: <https://susztaklab.com/GWAS2M/Download.php>

Reference publication: <https://www.science.org/doi/10.1126/science.adp4753>

### 5.2 FUMA Parameters

- Reference panel: African populations (1000 Genomes)
- LD threshold:  $r^2 > 0.6$
- Minor allele frequency:  $> 0.01$
- eQTL mapping: enabled
- MAGMA analysis: enabled

FUMA results: <https://fuma.ctglab.nl/browse/697303>

### 5.3 Questions

- How many putative genomic risk loci are identified using a genome-wide significance threshold of  $5 \times 10^{-8}$ ?
- Using regional association plots and SNPs in linkage disequilibrium (LD), how is each lead SNP supported by neighboring variants?
- What differences do you observe between loci in terms of effect size, LD structure, and number of supporting SNPs?
- Which loci or genomic regions have been previously reported in GWAS catalogs?
  - Which loci appear novel?
  - What are the limitations of assessing novelty using GWAS catalog overlap alone?
  - What additional analyses or external resources could be used to validate novelty?
- Using functional annotations and pathogenicity scores (e.g. CADD), which SNPs are predicted to be potentially pathogenic and in which genes?
- Which genes are identified as significant in the MAGMA gene-based analysis?
  - Which of these genes have been previously described in kidney-related traits?
  - How do gene-based results compare with SNP-level (locus-based) findings?
  - How would you interpret discrepancies between the two approaches?
- **African-ancestry considerations**

- Is the conventional genome-wide significance threshold ( $5 \times 10^{-8}$ ) appropriate for African-ancestry GWAS?
- How do higher genetic diversity and shorter LD blocks in African populations affect locus discovery and interpretation?
- How should significance thresholds be handled in trans-ethnic or multi-ancestry GWAS?
- What alternative strategies could be considered (e.g. ancestry-specific thresholds, empirical thresholds, replication-based validation)?